These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32744405)

  • 1. Synthesis of Novel Nitroxoline Analogs with Potent Cathepsin B Exopeptidase Inhibitory Activity.
    Van de Walle T; Briand M; Mitrović A; Sosič I; Gobec S; Kos J; Persoons L; Daelemans D; De Jonghe S; Ubiparip Z; Desmet T; Van Hecke K; Mangelinckx S; D'hooghe M
    ChemMedChem; 2020 Dec; 15(24):2477-2490. PubMed ID: 32744405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin B inhibitors: Further exploration of the nitroxoline core.
    Sosič I; Mitrović A; Ćurić H; Knez D; Brodnik Žugelj H; Štefane B; Kos J; Gobec S
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1239-1247. PubMed ID: 29503024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organoruthenated Nitroxoline Derivatives Impair Tumor Cell Invasion through Inhibition of Cathepsin B Activity.
    Mitrović A; Kljun J; Sosič I; Uršič M; Meden A; Gobec S; Kos J; Turel I
    Inorg Chem; 2019 Sep; 58(18):12334-12347. PubMed ID: 31464130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity.
    Mirković B; Markelc B; Butinar M; Mitrović A; Sosič I; Gobec S; Vasiljeva O; Turk B; Čemažar M; Serša G; Kos J
    Oncotarget; 2015 Aug; 6(22):19027-42. PubMed ID: 25848918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and related compounds.
    Mirković B; Renko M; Turk S; Sosič I; Jevnikar Z; Obermajer N; Turk D; Gobec S; Kos J
    ChemMedChem; 2011 Aug; 6(8):1351-6. PubMed ID: 21598397
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of endopeptidase and exopeptidase activity of cathepsin B impairs extracellular matrix degradation and tumour invasion.
    Mitrović A; Mirković B; Sosič I; Gobec S; Kos J
    Biol Chem; 2016 Jan; 397(2):165-74. PubMed ID: 26565553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
    Varshosaz J; Fard MM; Mirian M; Hassanzadeh F
    Anticancer Agents Med Chem; 2020; 20(3):346-358. PubMed ID: 31566137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents.
    Veschi S; Carradori S; De Lellis L; Florio R; Brocco D; Secci D; Guglielmi P; Spano M; Sobolev AP; Cama A
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1331-1344. PubMed ID: 32588672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitroxoline: repurposing its antimicrobial to antitumor application.
    Mitrović A; Kos J
    Acta Biochim Pol; 2019 Dec; 66(4):521-531. PubMed ID: 31834689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Assessment of 2,177 U.S. and International Drugs Identifies the Quinoline Nitroxoline as a Potent Amoebicidal Agent against the Pathogen
    Laurie MT; White CV; Retallack H; Wu W; Moser MS; Sakanari JA; Ang K; Wilson C; Arkin MR; DeRisi JL
    mBio; 2018 Oct; 9(5):. PubMed ID: 30377287
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
    Sosič I; Mirković B; Arenz K; Stefane B; Kos J; Gobec S
    J Med Chem; 2013 Jan; 56(2):521-33. PubMed ID: 23252745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.
    Jiang H; Xing J; Wang C; Zhang H; Yue L; Wan X; Chen W; Ding H; Xie Y; Tao H; Chen Z; Jiang H; Chen K; Chen S; Zheng M; Zhang Y; Luo C
    Org Biomol Chem; 2017 Nov; 15(44):9352-9361. PubMed ID: 29087414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The urinary antibiotic 5-nitro-8-hydroxyquinoline (Nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc.
    Sobke A; Klinger M; Hermann B; Sachse S; Nietzsche S; Makarewicz O; Keller PM; Pfister W; Straube E
    Antimicrob Agents Chemother; 2012 Nov; 56(11):6021-5. PubMed ID: 22926564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitroxoline induces apoptosis and slows glioma growth in vivo.
    Lazovic J; Guo L; Nakashima J; Mirsadraei L; Yong W; Kim HJ; Ellingson B; Wu H; Pope WB
    Neuro Oncol; 2015 Jan; 17(1):53-62. PubMed ID: 25074541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.
    El-Gohary NS; Shaaban MI
    Eur J Med Chem; 2018 Sep; 157():729-742. PubMed ID: 30138804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
    Chang WL; Hsu LC; Leu WJ; Chen CS; Guh JH
    Oncotarget; 2015 Nov; 6(37):39806-20. PubMed ID: 26447757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
    Veschi S; De Lellis L; Florio R; Lanuti P; Massucci A; Tinari N; De Tursi M; di Sebastiano P; Marchisio M; Natoli C; Cama A
    J Exp Clin Cancer Res; 2018 Sep; 37(1):236. PubMed ID: 30241558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline.
    Sobke A; Makarewicz O; Baier M; Bär C; Pfister W; Gatermann SG; Pletz MW; Forstner C
    Int J Antimicrob Agents; 2018 Feb; 51(2):213-220. PubMed ID: 29111434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity
    Mitrović A; Sosič I; Kos Š; Tratar UL; Breznik B; Kranjc S; Mirković B; Gobec S; Lah T; Serša G; Kos J
    Oncotarget; 2017 Aug; 8(35):59136-59147. PubMed ID: 28938624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells.
    Veschi S; Ronci M; Lanuti P; De Lellis L; Florio R; Bologna G; Scotti L; Carletti E; Brugnoli F; Di Bella MC; Bertagnolo V; Marchisio M; Cama A
    Sci Rep; 2020 Feb; 10(1):2574. PubMed ID: 32054977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.